Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity
or death, withdrawal of consent, lost to follow-up, or study termination from sponsor;
treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff
for final analysis.